Drug Profile
Choline alfoscerate sustained-release - Hyundai Pharmaceuticals
Alternative Names: HT-003 - Hyundai PharmaceuticalsLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Hyundai Pharmaceutical
- Class Antibacterials; Antidementias; Glycerophosphates; Glycerophospholipids; Neuroprotectants; Nootropics
- Mechanism of Action Cell membrane permeability enhancers; Cholinergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Cognition-disorders(In volunteers) in South Korea (PO, Controlled release)